首页> 外文期刊>Journal of the American College of Surgeons >Mesohepatectomy for centrally located hepatocellular carcinoma: an appraisal of a rare procedure.
【24h】

Mesohepatectomy for centrally located hepatocellular carcinoma: an appraisal of a rare procedure.

机译:中肝切除术用于中心性肝细胞癌:一种罕见手术的评估。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: For centrally located hepatocellular carcinoma (HCC), extended major hepatectomy is usually recommended, but the risk of postoperative liver failure is high when liver function is not sound. Mesohepatectomy (en bloc resection of Goldsmith and Woodburne's left medial and right anterior segments or Couinaud's segments IV, V, and VIII) is a rare procedure, so its role in treating HCC is unclear. STUDY DESIGN: We retrospectively reviewed 364 patients who underwent a curative resection for HCC. Among them, 15 patients were treated by mesohepatectomy. Their nontumorous liver revealed cirrhosis in 11 and chronic hepatitis in 4. The mean tumor diameter was 12.8 cm. In 10 of the 15 patients, HCC also invaded adjacent organs. The operative results of another 25 patients with different disease extent who underwent extended major hepatectomy were compared. RESULTS: The hepatic inflow occlusion time for mesohepatectomy was longer than for extended hepatectomy (p = 0.01). The mean operative blood loss, amount of blood transfusion, operating time, and postoperative hospital stay in the mesohepatectomy group were 2,450 mL, 1,100 mL, 7.9 hours, and 14.9 days, respectively. In the extended-hepatectomy group, the values were 1,863mL, 768mL, 5.8 hours, and 16.8 days, respectively (all p>0.05 compared with mesohepatectomy). No patient died after mesohepatectomy, but after extended hepatectomy there was one death from liver failure. The Union Internationale contre le cancer (UICC) TNM stages of patients who underwent mesohepatectomy were as follows: stage II in 1, stage III in 4, and stage IVA in 10. All patients who underwent extended hepatectomy presented with stage IVA disease. The 6-year disease-free and actuarial survival rates after mesohepatectomy were 21% and 30%, respectively. The 6-year disease-free survival rate after extended hepatectomy was 9% (p = 0.11 compared with mesohepatectomy). CONCLUSION: Although mesohepatectomy is time-consuming, it is justified for selected patients with centrally located large HCC in a diseased liver.
机译:背景:对于中心性肝细胞癌(HCC),通常建议行大面积肝切除术,但如果肝功能不健全,则术后肝衰竭的风险较高。中肝切除术(对戈德史密斯和伍德伯恩的左内侧和右前方节段或库纳氏IV,V和VIII节进行整块切除)是一种罕见的手术,因此尚不清楚其在治疗HCC中的作用。研究设计:我们回顾性分析了364例接受肝癌根治性切除术的患者。其中,有15例经中肝切除术治疗。他们的非肿瘤肝显示肝硬化11例,慢性肝炎显示4。平均肿瘤直径为12.8 cm。 15例患者中有10例HCC还侵犯了邻近器官。比较了另外25例不同疾病程度的患者,他们接受了大范围肝切除术。结果:中肝切除术的肝脏流入闭塞时间比扩大肝切除术的患者长(p = 0.01)。中肝切除术组的平均手术失血量,输血量,手术时间和术后住院时间分别为2,450 mL,1,100 mL,7.9小时和14.9天。在扩大肝切除术组中,该值分别为1,863mL,768mL,5.8小时和16.8天(与中肝切除术相比,所有p> 0.05)。中肝切除术后无患者死亡,但大面积肝切除术后因肝衰竭死亡1例。进行了中肝切除术的患者的国际结肠癌(UICC)TNM分期如下:II期分为1期,III期分为4期,IVA期为10期。所有接受了延长肝切除术的患者均患有IVA期疾病。中肝切除术后6年无病生存率和精算生存率分别为21%和30%。扩大肝切除术后6年无病生存率为9%(与中肝切除术相比,p = 0.11)。结论:尽管中肝切除术很耗时,但对于某些患病肝脏中位于中心的大肝癌的患者来说,这是合理的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号